Boehringer Ingelheim
Global, independent biopharmaceutical company active in human and animal health. Large investor in research and development with capabilities spanning drug discovery, clinical development, regulatory submissions, biopharmaceutical manufacturing, vaccine development, and digital health solutions. Operates global clinical programs and partnerships across oncology, respiratory, cardio-renal-metabolic and other therapeutic areas.
Industries
Nr. of Employees
Very Large (1000+)
Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, CT 06877
Products
Prescription Medicines
Medicinal products prescribed by healthcare professionals to treat various human diseases and conditions.
Animal Health Products
Medicinal and health products designed for the treatment and prevention of diseases in animals.
Prescription Medicines
Medicinal products prescribed by healthcare professionals to treat various human diseases and conditions.
Animal Health Products
Medicinal and health products designed for the treatment and prevention of diseases in animals.
Services
End-to-end clinical development services including protocol design, site network activation, global trial conduct and data collection.
Licensing, collaboration and asset-integration services to advance externally sourced or co-developed therapeutic programs into clinical development.
Development and commercialization of in-house digital tools aimed at patient safety and clinical workflows.
Large-scale production and contract manufacturing services for biologics and other biopharmaceuticals.
End-to-end clinical development services including protocol design, site network activation, global trial conduct and data collection.
Licensing, collaboration and asset-integration services to advance externally sourced or co-developed therapeutic programs into clinical development.
Development and commercialization of in-house digital tools aimed at patient safety and clinical workflows.
Large-scale production and contract manufacturing services for biologics and other biopharmaceuticals.
Expertise Areas
- Clinical trial management
- Pulmonary fibrosis research and development
- Oncology drug development
- Antibody-drug conjugate (ADC) development
Key Technologies
- Antibody-drug conjugates (ADCs)
- Monoclonal antibody engineering
- Small-molecule PDE4B inhibitors
- Randomized double-blind placebo-controlled clinical trials
News & Updates
Topline data show investigational preferential PDE4B inhibitor met the primary endpoint (absolute change in FVC at week 52 versus placebo); company to submit regulatory applications.
Global collaboration and license agreement to advance an antibody-drug conjugate asset into first-in-human studies.
Overview of the role of biomarker testing in personalizing treatment for non-small cell lung cancer.
An investigational PDE4B inhibitor program was granted Breakthrough Therapy designation by the US FDA for idiopathic pulmonary fibrosis.
Received positive opinions from the Committee for Medicinal Products for Veterinary Use for two avian influenza vaccine candidates.
Topline data show investigational preferential PDE4B inhibitor met the primary endpoint (absolute change in FVC at week 52 versus placebo); company to submit regulatory applications.
Global collaboration and license agreement to advance an antibody-drug conjugate asset into first-in-human studies.
Overview of the role of biomarker testing in personalizing treatment for non-small cell lung cancer.
An investigational PDE4B inhibitor program was granted Breakthrough Therapy designation by the US FDA for idiopathic pulmonary fibrosis.
Received positive opinions from the Committee for Medicinal Products for Veterinary Use for two avian influenza vaccine candidates.